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Abstract  
Curcumin is a polyphenol derived from the golden spice turmeric, which is widely used for different purposes, 
such as culinary spice and alimentary addictive, make - up and, finally, as a natural product for the treatment of 
different diseases, especially for the chronic inflammatory ones. Recently, curcumin has been proposed as a valid 
and safe therapeutic option for psoriasis. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The traditional medicine, based on the 
administration of natural and herbal products for the 
treatment of several human diseases, has been 
employed by many different cultures throughout 
history, becoming today a real multi millionary 
industry, with a recorded cost of USD 10 billion/year 
[1]. 
Among the numerous herbal compounds 
available for the medical purpose, there is Curcumin, 
a polyphenol derived from the golden spice turmeric 
(“Curcuma longa”), of the Zinzigiberaceae family, 
characterised by many properties [2]. 
Since ancient time, Curcumin has been widely 
used for different purposes, such as culinary spice 
and alimentary addictive (e.g. ice cream, yogurt, 
orange juice, biscuits, popcorn, cakes, cereals, 
sauces, gelatins), make - up and, finally, as natural 
product for the treatment of different diseases, 
especially for the chronic inflammatory ones [3]. 
Although, its well - known effectiveness as a 
therapeutic herb, curcumin pharmacological 
properties have been scientifically proved only in the 
last century [4][5]. Today, it is clear how the wide 
range of use of curcumin in medicine is the result of 
its numerous properties, such as antioxidant, anti-
inflammatory, anti - proliferative, anti-carcinogenic and 
anti-microbial ones [6][7]. 
In medicine, curcumin is used for the 
treatment of different diseases [3], like rheumatoid 
arthritis, eye diseases (e.g. chronic anterior uveitis, 
conjunctivitis), urinary tract infections, menstrual 
alterations, liver and gastrointestinal disorders (e.g. 
abdominal pain, inflammatory bowel disease) 
[3][8][9][10]. Furthermore, curcumin is used as 
adjuvant therapy for the treatment of skin cancers, 
chicken pox and wound healing [5][6]. 
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Even if it may be assumed with diet, curcumin 
is now formulated into tablets, at a different dosage, 
often associated to particular adjuvants (e.g. piperine, 
phospholipids), which lead to improving its absorption 
and bioavailability [11]. 
 
 
Curcumin and psoriasis 
 
 Psoriasis is a chronic, inflammatory, cell-
mediated disease, which involves the skin, and 
sometimes joints, bones, tendons, ligaments, nails, 
and mucosal membranes. Although it may represent 
with different clinical variants, the most commonly 
described is the “vulgaris” one, which is characterised 
by erythematous round or oval lesions, covered by 
white-silvery scales. Cutaneous lesions are usually 
localised on the elbows, knees, scalp and lumbar-
sacral region in a symmetric pattern, even if they can 
affect different body areas [12]. 
Despite the availability of different topical and 
systemic therapeutic options for the treatment of 
psoriasis [13][14][15][16][17], none of them provides 
excellent clinical results without the risk of side effects 
(Table 1). 
Table 1: Common antipsoriatic therapies 
Drugs MoA 
TOPICAL Corticosteroids Immunosoppressive; anti-inflammatory; anti- 
proliferative; vasocostriction 
 Soothing: urea, allantoin, lanolin Anti-inflammatory 
 Keratolytics: salicylic acid 3 - 6%, 
Αlpha - Hydroxy acids (lactic acid, 
propylene glycol), emollients, bath 
↓ cell – to - cell cohesion in the stratum corneum 
→ 
Help to remove accumulated scales or 
hyperkeratosis 
 Anthralin (Dithranol, 1, 8 – 
Dihydroxy – 9 - anthrone) 
Anti - proliferative effect; anti-inflammatory effect 
 Tars (coal tars and wood tars ) Keratoplastic; anti-acanthotic; photosensitizing 
(absorption spectrum of 330-550 nm); 
vasocostrictive 
 Retinoids: tarazotene Normalize the abnormal differentiation of 
keratinocytes; antiproliferative affects on 
keratinocytes; ↓ expression of inflammatory 
markers on keratinocytes (e.g. HLA - DR, ICAM - 
I) 
 Derivatives and analogues of 
vitamin D3: calcipotriol, tacalcitol,  
calcitriol 
Regulation of epidermal hyperproliferation; 
enhancement of normal keratinisation; 
immunomodulating; anti-inflammatory; 
angiogenesis inhibition 
 Calcineurin inhibitors: Tacrolimus, 
Pimecrolimus 
Immunosuppression 
PHOTOTHERAPY PUVA therapy Cell cycle arrest; immunosuppression 
 UVB, nbUVB, excimer laser Cell cycle arrest; immunosoppression 
SYSTEMIC Methotrexate Antiproliferative; anti-inflammatory 
 Acitretin Normalize the abnormal differentiation of 
keratinocytes; antiproliferative affects on 
keratinocytes 
 Cyclosporin A Inhibition of CD4 T cells 
 Fumaric acid esters Immunomodulation 
 Hydroxyurea Regulation of proliferating cells 
 Sulfasalazine Antiinflammatory 
 Mycophenolate mofetil Immunomodulator 
 6 - Thioguanine Cell cycle arrest 
BIOLOGICS Etanercep, Infliximab, 
Adalimumab 
Anti TNFα 
 
In the last years, an increasing number of 
studies underline the potential use of curcumin in the 
treatment of psoriasis. Many are the evidence which 
supports its therapeutic efficacy. The first one is that 
curcumin, with its antioxidative property, may reduce 
the oxidative stress of psoriatic lesions [18]. More 
recently, two different studies showed how curcumin 
therapeutic efficacy might also be related to its ability 
in inhibiting the phosphorylase kinases, which are 
increased in psoriatic patients [19][20]. Also 
interesting are the results, achieved by Varma et Al., 
about the use of curcumin at 25 and 50 µM 
concentrations in the treatment of psoriatic - like cells 
(HaCaT cells), in vitro. The authors showed how 
curcumin was able to inhibit the proliferation of 
psoriatic - like cells, by the down-regulation of pro-
inflammatory cytokines, such as interleukin - 17, 
tumour necrosis factor - α, interferon - γ and 
interleukin - 6. Moreover, curcumin significantly 
enhanced the skin - barrier function by the up-
regulation of involucrin (iNV) and filaggrin (FLG) [21]. 
Recently, Kang D. et Al. have proved, on mice 
models, another important effect of curcumin, 
consisting in the inhibition of the potassium channels 
(subtypes Kv1.3) expressed on T cells, which seem to 
be involved in the onset of psoriasis. The anti-
inflammatory properties of curcumin, have been 
confirmed by the finding that mice, showed in their 
serum a decrease of more than 50% level of 
inflammatory factors, including TNF -  α, IFN - γ, IL - 
2, IL - 12, IL - 22 and IL - 23 [22]. 
No study in vivo have shown side effects of 
curcumin in the treatment of psoriatic patients [23][24], 
and the U.S. Food and Drug Administration (FDA) has 
defined curcumin as “generally regarded as safe” 
(GRAS). 
In conclusion, curcumin is a polyphenol 
derived from the golden spice turmeric (“Curcuma 
longa”). Because of its numerous properties (e.g. anti 
- oxidant, anti -proliferative, anti-inflammatory, 
antiviral, antibacterial and antifungal properties), 
curcumin has been used for the treatment of different 
diseases [25]. Recently it has been proposed for the 
treatment of psoriasis, where its efficacy seems to be 
the result of different mechanism of actions. Even if 
different studies, both in vitro and in vivo, have shown 
its efficacy and safe profile, further placebo-controlled 
studies are needed before recommending oral 
curcumin as a valid treatment for psoriasis. 
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